New combo therapy targets rare bone cancer with immune-boosting drug
NCT ID NCT07115667
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tests whether combining radiation with a bispecific antibody (CM336) can safely treat solitary bone plasmacytoma that has mild bone marrow involvement. About 21 adults with this rare plasma cell disorder will receive the combination therapy. The goal is to control the disease and prevent it from progressing to multiple myeloma, but ongoing monitoring is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLITARY BONE PLASMACYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.